Tradr 2X Long IBM Daily ETF (IBX)
| Assets | $32.69M |
| Expense Ratio | 1.30% |
| PE Ratio | n/a |
| Shares Out | 1.92M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 401,213 |
| Open | 17.08 |
| Previous Close | 17.05 |
| Day's Range | 17.08 - 17.87 |
| 52-Week Low | 12.91 |
| 52-Week High | 42.33 |
| Beta | n/a |
| Holdings | 4 |
| Inception Date | Mar 23, 2026 |
About IBX
Fund Home PageThe Tradr 2X Long IBM Daily ETF (IBX) is an exchange-traded fund that mostly invests in information technology equity. The fund seeks to deliver 200% leveraged exposure to the daily share price movement of International Business Machines Corp. (NYSE: IBM), net of fees and expenses, through derivatives like swap agreements. IBX was launched on Mar 23, 2026 and is issued by Tradr.
Top Holdings
| Name | Symbol | Weight |
|---|---|---|
| Cfd Intl Business Machines Corp | n/a | 200.00% |
| Cashusd | n/a | 105.95% |
| Net Other Assets | n/a | -16.74% |
| Cfd Intl Business Machines Corp | n/a | -189.21% |
Performance
News
Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--IBX announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA's clearance of IND for a Phase 2 trial.
Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--Imagion's IND Application for HER2 MagSense® Imaging Agent Phase 2 Clinical Trial Has Cleared FDA Review. Company to proceed with clinical trial.
Tradr Set to Launch Leveraged ETFs on AMZN, AAOI, HL and IBM
All four strategies represent first-to-market exposures on emerging growth and blue-chip stocks NEW YORK, March 23, 2026 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated inves...